Some providers will prescribe compounded tirzepatide off-label in this scenario, but it represents a misuse of the medication
Dysfunctional decision-making in binge-eating disorder: a meta-analysis and systematic review
Step-by-step activation is available, and current members have already been updated
Semaglutide has received FDA approval for distinct clinical indications based on formulation and dosing regimen, reflecting its versatility as a GLP-1 receptor agonist
Its unique molecular structure allows it to provide comprehensive protection at the cellular level
Clinical Trial Evidence for Wegovy Wegovy approval was supported by large, randomized clinical trials, including the STEP 1 study: 1,961 adults with obesity or overweight plus weight-related health conditions 68-week study duration Average weight loss of approximately 14.9% of body weight 86% of participants lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Participants followed reduced-calorie diets and increased physical activity Before receiving FDA approval, GLP-1 medications completed Phase I, Phase II, and Phase III trials
